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Background: Lipoatrophy is a frequent complication of chronic stavudine therapy. Stavudine 
extended release formulation (stavudine ER) gives lower peak and higher trough levels than 
the immediate release formulation (stavudine IR), and we hypothesized that the lower peak 
might result in less lipoatrophy. Objective: To compare the rate of peripheral lipoatrophy 
between patients taking stavudine ER and stavudine IR. Method: Body composition was 
measured by dual energy X-ray absorptiometry (DEXA) every 6 months for 18 months in 29 
patients taking either stavudine ER or IR as part of a randomized controlled clinical trial. 
Results: DEXA fat measurements did not differ between the ER and IR groups at baseline, 
after a median of 32 months on stavudine-containing treatment. Over the 18 months of follow-
up in the whole cohort limb fat decreased by a mean of 0.29 ± 0.50 kg (p = .01) and leg fat 
percent decreased by a mean of 1.23% ± 1.92% (p = .001), whereas trunk fat and trunk-to-
limb fat percent ratio did not change significantly. There was no significant difference between 
the ER and IR groups in the rate of change of any of the fat parameters. At study completion, 
the proportion of patients with clinical lipodystrophy was similar in the stavudine ER and 
stavudine IR groups (67% and 64%, respectively; p = .893). Conclusion: Stavudine ER does 
not appear to cause less peripheral lipoatrophy. 
